ESR1 and breast carcinoma: Early gene expression studies [1-6] classify breast cancer into at least three clinically relevant molecular subtypes: basal-like (predominantly estrogen receptor (ER) negative and human epidermal growth factor receptor 2 (HER2) negative), HER2-positive, and luminal-like (ER-positive) tumors.